Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 11 recruiting now early-phase tilt small index

Severe Aplastic Anemia: early-phase trial registry

11 of 17 indexed Severe Aplastic Anemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,004 of 28,707 conditions by registered trial count.

17 US clinical trials · 11 currently recruiting · #1,004 of 28,707 conditions by registered trial count

Severe Aplastic Anemia: 17 US clinical trials tracked, 11 recruiting.

Severe Aplastic Anemia is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 7 of these trials.

Enrollment posture brief

Registry condition severe-aplastic-anemia

OPEN 11 | RECR 65% | LATE 1 | EARLY 14 | RANK #1004 | SPON 7

Nearest open-share peer: Autism Spectrum Disorder (ASD) (65% recruiting · 17 trials)

Acute Myeloid Leukemia, in R70.6%Severe Aplastic Anemia (this)65%Abdominal Aortic Aneurysm52.9%Acute Lymphoblastic Leukemia23.5%Actinic Keratosis11.8%
Open-enrollment share among volume-matched conditions near Severe Aplastic Anemia

Severe Aplastic Anemia lists 11 open slots (65% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Severe Aplastic Anemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Severe Aplastic Anemia is recruiting above its size-band peers.

    11 of 17 indexed trials (64.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Severe Aplastic Anemia research.

    National Heart, Lung, and Blood Institute (NHLBI) accounts for 7 of 17 trials (41.2%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Severe Aplastic Anemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 53 among the 17 trials that report a genuine target (sentinel values excluded). 13 of those (76.5%) plan for fewer than 100 participants.

  4. Severe Aplastic Anemia research is mostly interventional.

    16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 210Phase 31

Open and recent trials

17 total, page 1 of 1

RECRUITING 1,000 participants

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

National Heart, Lung, and Blood Institute (NHLBI)

NCT05012111

RECRUITING Phase 1 145 participants

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

National Heart, Lung, and Blood Institute (NHLBI)

NCT05998408

RECRUITING Phase 2 120 participants

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

National Heart, Lung, and Blood Institute (NHLBI)

NCT01174108

RECRUITING Phase 2 80 participants

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

National Heart, Lung, and Blood Institute (NHLBI)

NCT04304820

RECRUITING Phase 2 60 participants

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

Medical College of Wisconsin

NCT06517641

RECRUITING Phase 2 60 participants

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Masonic Cancer Center, University of Minnesota

NCT06412497

RECRUITING Phase 2 48 participants

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Masonic Cancer Center, University of Minnesota

NCT03579875

RECRUITING Phase 1 37 participants

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

National Heart, Lung, and Blood Institute (NHLBI)

NCT03173937

RECRUITING Phase 2 20 participants

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Northside Hospital

NCT02828592

RECRUITING Phase 2 20 participants

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Mitchell Cairo

NCT04099966

RECRUITING Phase 2 17 participants

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

Johns Hopkins All Children's Hospital

NCT04356469

ACTIVE NOT RECRUITING Phase 1 207 participants

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

National Heart, Lung, and Blood Institute (NHLBI)

NCT01623167

ACTIVE NOT RECRUITING Phase 2 84 participants

Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

National Heart, Lung, and Blood Institute (NHLBI)

NCT02979873

ACTIVE NOT RECRUITING Phase 3 53 participants

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Boston Children's Hospital

NCT05600426

ACTIVE NOT RECRUITING Phase 1 37 participants

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

Diane George

NCT01966367

ACTIVE NOT RECRUITING NA 3 participants

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

Baylor College of Medicine

NCT05236764

COMPLETED Phase 2 36 participants

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

University of California, San Francisco

NCT00516152

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 10
Phase 3 1

Named interventions

Most-linked intervention names on Severe Aplastic Anemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Rabbit ATG Drug
2 trials
Total Body Irradiation Radiation
2 trials
Fludarabine Drug
2 trials
Cyclophosphamide Drug
2 trials
Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF Drug
1 trials
rabbit anti-thymocyte globulin (ATG) Drug
1 trials
horse anti-thymocyte globulin (ATG) Drug
1 trials
Matched Unrelated Donor Hematopoetic Stem Cell Transplant Procedure
1 trials

US sites by state

Facility locations filed on Severe Aplastic Anemia trials. A trial with sites in several states counts in each.

Maryland 8 trials
New York 3 trials
Minnesota 3 trials
Georgia 3 trials
Florida 3 trials
California 3 trials
Alabama 2 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Severe Aplastic Anemia page

17 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Severe Aplastic Anemia condition card totals 17 registered trials; most-linked intervention Rabbit ATG; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.